Source:http://linkedlifedata.com/resource/pubmed/id/12040283
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2002-5-31
|
pubmed:abstractText |
The aim of this study was to identify the impact of various prognostic factors in the management of uterine sarcoma. Fifty-nine patients with uterine sarcoma were treated at King Faisal Specialist Hospital and Research Center between 1980 and 1997. Forty-three patients (73%) were treated by total abdominal hysterectomy and bilateral salpingo-oophorectomy, 7 (12%) total abdominal hysterectomy and bilateral salpingo-oophorectomy with sampling of pelvic lymph nodes, and 9 (15%) had biopsy only. Nine patients received adjuvant treatment; five had radiation therapy (XRT), two had chemotherapy, one had combined XRT and chemotherapy, and one received hormonal treatment. Leiomyosarcoma cases accounted for 42% of all the uterine sarcomas, carcinosarcoma cases for 34%, and endometrial stromal sarcoma (ESS) for 24%. Fifty (85%) patients had pathologic grade II and III tumor, with only 9 patients grade I. Twenty-seven patients (46%) were classified surgically as stage I, 7 (12%) as stage II, 17 (29%) as stage III, and 8 (13%) had stage IV tumor. Recurrences developed in 34 patients (71%). The 5- and 10-year overall actuarial survival for all patients was 42%, and the corresponding relapse-free survivals for those who achieved complete response after primary treatment (48 patients) were 27% and 20%. On the univariate analysis, grade I tumors (p = 0.04), ESS (p = 0.02), nonmetastatic stage (p = 0.05), and negative peritoneal cytology (p = 0.04) were associated with better overall survival. Factors associated
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0277-3732
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
25
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
256-60
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:12040283-Adolescent,
pubmed-meshheading:12040283-Adult,
pubmed-meshheading:12040283-Aged,
pubmed-meshheading:12040283-Antineoplastic Agents,
pubmed-meshheading:12040283-Combined Modality Therapy,
pubmed-meshheading:12040283-Female,
pubmed-meshheading:12040283-Humans,
pubmed-meshheading:12040283-Hysterectomy,
pubmed-meshheading:12040283-Lymph Node Excision,
pubmed-meshheading:12040283-Middle Aged,
pubmed-meshheading:12040283-Multivariate Analysis,
pubmed-meshheading:12040283-Ovariectomy,
pubmed-meshheading:12040283-Prognosis,
pubmed-meshheading:12040283-Radiotherapy Dosage,
pubmed-meshheading:12040283-Sarcoma,
pubmed-meshheading:12040283-Survival Analysis,
pubmed-meshheading:12040283-Uterine Neoplasms
|
pubmed:year |
2002
|
pubmed:articleTitle |
Prognostic factors and treatment modalities in uterine sarcoma.
|
pubmed:affiliation |
Department of Radiation Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
|
pubmed:publicationType |
Journal Article
|